Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024, where revenue and net income grew from the previous year, and a positive outlook for 2025 sales excluding Veklury, investor confidence appears bolstered. Additionally, the general market saw a modest recovery with Nasdaq appreciating, although tech stocks were more positively impacted. The 2.6% dividend increase also suggests strong financial health, likely enhancing Gil
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025 [Yahoo! Finance]Yahoo! Finance
- GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive [Yahoo! Finance]Yahoo! Finance
- Vantis Health completes €10m funding round to advance primary care [Yahoo! Finance]Yahoo! Finance
- Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy OptionBusiness Wire
- First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The LancetBusiness Wire
GILD
Earnings
- 2/11/25 - Beat
GILD
Sec Filings
- 3/12/25 - Form 4
- 3/12/25 - Form 4
- 3/12/25 - Form 4
- GILD's page on the SEC website